Description du projet
Nouveau nanomédicament pour le cancer du pancréas
Le cancer du pancréas est considéré comme l’un des types de cancer les plus agressifs, qui reste souvent non détecté à ses débuts en raison de l’absence de symptômes spécifiques. Il se caractérise par un mauvais pronostic global, un faible taux de survie et des options thérapeutiques limitées. Afin d’offrir des alternatives de traitement aux patients, le projet NoCanTher, financé par l’UE, entend mettre au point des nanoparticules fonctionnalisées pour cibler les cellules cancéreuses du pancréas et administrer un médicament anticancéreux. Les chercheurs présenteront cette nanoformulation en vue d’un développement clinique, ce qui implique d’augmenter la production dans des conditions certifiées et d’optimiser divers paramètres pour l’utilisation chez les patients.
Objectif
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.
The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.
NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:
• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process.
• Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).
This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).
Champ scientifique
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicineoncologybreast cancer
- engineering and technologynanotechnologynano-materials
- medical and health sciencesclinical medicineoncologypancreatic cancer
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
28049 Madrid
Espagne